Perseus Proteomics : Adoption of Research and Development as Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation by AMED

March 23, 2022

Perseus Proteomics Inc.

Securities Code: 4882 Mothers TSE

To all stakeholders,

Adoption of Research and Development as Project Promoting Support for Drug Discovery

Support Program for Orphan drug prior to the Designation by Japan Agency

for Medical Research and Development (AMED)

Perseus Proteomics Inc. ("the Company") is pleased to announce that the research and development of the Company on utilizing its pipeline drug candidate as therapeutic drug for aggressive NK cell leukemia ("ANKL") has been adopted as Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation by AMED.

1. Title of the adopted research and development: "Development of Therapeutic Drug for Aggressive NK Cell Leukemia"
2. Representative organization: Perseus Proteomics Inc.
3. Outline and purpose of the research

ANKL is a blood cancer categorized as malignant lymphoma, which originates in NK (natural killer) cells, one of immune cells. It is very rare, fulminant type of refractory hematological malignancy, where symptoms will progress rapidly once developed.

The research group of Dr. Ai Kotani at Division of Hematological Malignancy, Institute of Medical Sciences, Tokai University has been aiming at the basic research through to development of new treatment method for such refractory hematological malignancy. Dr. Kotani's research group and the Company have been conducting research and development on new therapeutic drug of ANKL. Following this adoption by AMED, the research group and the Company will aim at a clinical trial and practical application of the research findings.

This subsidy project will continue for three years from the fiscal year 2022 to the fiscal year 2025. In the fiscal year 2022, the Company expects to receive approximately 50 million yen as subsidy, however, the actual amount will be determined after the inspection to be conducted after the end of respective project period by AMED.

4. Future forecast

The Company is studying the impact on the business results of the fiscal year 2022 and disclose the forecast for the fiscal year 2022 business results on May 13, 2022.

AMED program website

1 / 2

Dr. Kotani at Tokai University website(Japanese only)

END

2 / 2